These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32158194)

  • 1. Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.
    Hu K; Zhu Z; Mathahs MM; Tran H; Bommer J; Testa CA; Schmidt WN
    Drug Des Devel Ther; 2020; 14():757-771. PubMed ID: 32158194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring small molecules with pan-genotypic inhibitory activities against hepatitis C virus NS3/4A serine protease.
    Ren J; Ojeda I; Patel M; Johnson ME; Lee H
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2349-2353. PubMed ID: 31201062
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Ng TI; Tripathi R; Reisch T; Lu L; Middleton T; Hopkins TA; Pithawalla R; Irvin M; Dekhtyar T; Krishnan P; Schnell G; Beyer J; McDaniel KF; Ma J; Wang G; Jiang LJ; Or YS; Kempf D; Pilot-Matias T; Collins C
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084747
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches.
    Ezat AA; Elshemey WM
    Life Sci; 2019 Jan; 217():176-184. PubMed ID: 30528183
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliverdin inhibits hepatitis C virus nonstructural 3/4A protease activity: mechanism for the antiviral effects of heme oxygenase?
    Zhu Z; Wilson AT; Luxon BA; Brown KE; Mathahs MM; Bandyopadhyay S; McCaffrey AP; Schmidt WN
    Hepatology; 2010 Dec; 52(6):1897-905. PubMed ID: 21105106
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227).
    Seiwert SD; Andrews SW; Jiang Y; Serebryany V; Tan H; Kossen K; Rajagopalan PT; Misialek S; Stevens SK; Stoycheva A; Hong J; Lim SR; Qin X; Rieger R; Condroski KR; Zhang H; Do MG; Lemieux C; Hingorani GP; Hartley DP; Josey JA; Pan L; Beigelman L; Blatt LM
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4432-41. PubMed ID: 18824605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended interaction networks with HCV protease NS3-4A substrates explain the lack of adaptive capability against protease inhibitors.
    Dultz G; Shimakami T; Schneider M; Murai K; Yamane D; Marion A; Zeitler TM; Stross C; Grimm C; Richter RM; Bäumer K; Yi M; Biondi RM; Zeuzem S; Tampé R; Antes I; Lange CM; Welsch C
    J Biol Chem; 2020 Oct; 295(40):13862-13874. PubMed ID: 32747444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low susceptibility of asunaprevir towards R155K and D168A point mutations in HCV NS3/4A protease: A molecular dynamics simulation.
    Kammarabutr J; Mahalapbutr P; Nutho B; Kungwan N; Rungrotmongkol T
    J Mol Graph Model; 2019 Jun; 89():122-130. PubMed ID: 30884449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restoration of type I interferon expression by heme and related tetrapyrroles through inhibition of NS3/4A protease.
    Zhu Z; Mathahs MM; Schmidt WN
    J Infect Dis; 2013 Nov; 208(10):1653-63. PubMed ID: 23901085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring of paritaprevir and glecaprevir resistance due to A156T mutation of HCV NS3/4A protease: molecular dynamics simulation study.
    Boonma T; Nutho B; Darai N; Rungrotmongkol T; Nunthaboot N
    J Biomol Struct Dyn; 2022 Aug; 40(12):5283-5294. PubMed ID: 33430709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QSAR studies of the bioactivity of hepatitis C virus (HCV) NS3/4A protease inhibitors by multiple linear regression (MLR) and support vector machine (SVM).
    Qin Z; Wang M; Yan A
    Bioorg Med Chem Lett; 2017 Jul; 27(13):2931-2938. PubMed ID: 28501513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G; Sandström A; Akerblom E; Danielson UH
    Antivir Ther; 2007; 12(5):733-40. PubMed ID: 17713156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
    Li YP; Ramirez S; Humes D; Jensen SB; Gottwein JM; Bukh J
    Gastroenterology; 2014 Mar; 146(3):812-821.e4. PubMed ID: 24262279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
    Taylor JG; Zipfel S; Ramey K; Vivian R; Schrier A; Karki KK; Katana A; Kato D; Kobayashi T; Martinez R; Sangi M; Siegel D; Tran CV; Yang ZY; Zablocki J; Yang CY; Wang Y; Wang K; Chan K; Barauskas O; Cheng G; Jin D; Schultz BE; Appleby T; Villaseñor AG; Link JO
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2428-2436. PubMed ID: 31133531
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
    Xue W; Ban Y; Liu H; Yao X
    J Chem Inf Model; 2014 Feb; 54(2):621-33. PubMed ID: 23745769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system.
    He Y; King MS; Kempf DJ; Lu L; Lim HB; Krishnan P; Kati W; Middleton T; Molla A
    Antimicrob Agents Chemother; 2008 Mar; 52(3):1101-10. PubMed ID: 18086851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies.
    Gal-Tanamy M; Zemel R; Bachmatov L; Jangra RK; Shapira A; Villanueva RA; Yi M; Lemon SM; Benhar I; Tur-Kaspa R
    Antiviral Res; 2010 Oct; 88(1):95-106. PubMed ID: 20705106
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6.
    Imhof I; Simmonds P
    J Virol; 2010 May; 84(9):4597-610. PubMed ID: 20164226
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and antiviral activity of HCV NS3/4A peptidomimetic boronic acid inhibitors.
    Boloor A; Hanway D; Joshi M; Winn DT; Mendez G; Walls M; Wei P; Qian F; Zhang X; Zhang Y; Hepperle ME; Li X; Campbell DA; Betancort JM
    Bioorg Med Chem Lett; 2009 Oct; 19(19):5708-11. PubMed ID: 19713109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.